Cognitive disorders involve disturbances in information processing and integration associated with cognitive impairment and/or progressive cognitive decline. These disorders can be studied using translational EEG biomarkers that represent powerful assets to assess procognitive or anti-psychotic treatments efficacy. Our programs feature expertise in developping models of cognitive impairment, validating appropriate methods that seamlessly translate into the clinic (Auditory-evoked potentials, pharmaco-induced models) and skills in analysing complex data sets.

Introducing 40Hz ASSR – Translational Biomarker for Schizophrenia

Want to know more?
Please check out our article on LinkedIn:

Improving Early Decision-Making in Schizophrenia Drug Discovery with Predictive Biomarkers.

Applications: Autism spectrum disorders (ASD), Schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Epilepsy

Markers: ERPs, EROs, MMN, Gating, Multisite Coherence

Models: NMDA antagonists, Scopolamine. For other models, please contact us.

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping